(Q37810958)

23 August 2017

title

Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation (English)

1 reference

23 August 2017

main subject

organ transplantation

1 reference

3

Gerald Brandacher

1 reference

23 August 2017

5

Johann Pratschke

1 reference

23 August 2017

author name string

Annemarie Weissenbacher

1

1 reference

23 August 2017

Claudia Boesmueller

2

1 reference

23 August 2017

Robert Oellinger

4

1 reference

23 August 2017

Stefan Schneeberger

6

1 reference

23 August 2017

language of work or name

1 reference

1 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

2

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

783-790

1 reference

Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin

23 August 2017

cites work

1 reference

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

21 January 2018

1 reference

Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation

21 January 2018

1 reference

Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation

21 January 2018

1 reference

Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation

21 January 2018

1 reference

The use of Campath-1H as induction therapy in renal transplantation: preliminary results

21 January 2018

1 reference

Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath

21 January 2018

1 reference

Campath-1H in intestinal and multivisceral transplantation: preliminary data

21 January 2018

1 reference

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

21 January 2018

1 reference

Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation

21 January 2018

1 reference

Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial

21 January 2018

1 reference

Kidney after nonrenal transplantation-the impact of alemtuzumab induction

21 January 2018

1 reference

Alemtuzumab (Campath-1H): a systematic review in organ transplantation

21 January 2018

1 reference

Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results

21 January 2018

1 reference

Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation

21 January 2018

1 reference

Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation

21 January 2018

1 reference

A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.

21 January 2018

1 reference

Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus

21 January 2018

1 reference

Pediatric liver transplant with Campath 1H induction--Preliminary report

21 January 2018

1 reference

Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation

21 January 2018

1 reference

Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation.

21 January 2018

1 reference

Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy

21 January 2018

1 reference

Early outcomes using alemtuzumab induction in lung transplantation

21 January 2018

1 reference

Atypical acute rejection after hand transplantation.

21 January 2018

1 reference

Alemtuzumab: key for minimization of maintenance immunosuppression in reconstructive transplantation?

21 January 2018

1 reference

Transplantation of the abdominal wall

21 January 2018

1 reference

A personal history of the CAMPATH-1H antibody

21 January 2018

1 reference

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

21 January 2018

1 reference

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

21 January 2018

1 reference

Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.

21 January 2018

1 reference

A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation.

21 January 2018

1 reference

Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion.

21 January 2018

1 reference

Campath-1H induction and the incidence of infectious complications in adult renal transplantation

21 January 2018

1 reference

Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.10.68

1 reference

23 August 2017

1 reference